231 related articles for article (PubMed ID: 15544491)
1. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics.
Arora V; Devi GR; Iversen PL
Curr Pharm Biotechnol; 2004 Oct; 5(5):431-9. PubMed ID: 15544491
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.
Amantana A; Iversen PL
Curr Opin Pharmacol; 2005 Oct; 5(5):550-5. PubMed ID: 16087398
[TBL] [Abstract][Full Text] [Related]
3. Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds.
Nan Y; Zhang YJ
Front Microbiol; 2018; 9():750. PubMed ID: 29731743
[TBL] [Abstract][Full Text] [Related]
4. Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation.
Iversen PL
Curr Opin Mol Ther; 2001 Jun; 3(3):235-8. PubMed ID: 11497346
[TBL] [Abstract][Full Text] [Related]
5. Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers.
Ghosh C; Iversen PL
Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):263-74. PubMed ID: 10984120
[TBL] [Abstract][Full Text] [Related]
6. Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides.
Dirin M; Winkler J
Expert Opin Biol Ther; 2013 Jun; 13(6):875-88. PubMed ID: 23451977
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on antisense therapy for the prevention of restenosis.
Kipshidze N; Moses J; Shankar LR; Leon M
Curr Opin Mol Ther; 2001 Jun; 3(3):265-77. PubMed ID: 11497351
[TBL] [Abstract][Full Text] [Related]
9. Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity.
Nelson MH; Stein DA; Kroeker AD; Hatlevig SA; Iversen PL; Moulton HM
Bioconjug Chem; 2005; 16(4):959-66. PubMed ID: 16029037
[TBL] [Abstract][Full Text] [Related]
10. Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli.
Tilley LD; Mellbye BL; Puckett SE; Iversen PL; Geller BL
J Antimicrob Chemother; 2007 Jan; 59(1):66-73. PubMed ID: 17079242
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc.
Hudziak RM; Summerton J; Weller DD; Iversen PL
Antisense Nucleic Acid Drug Dev; 2000 Jun; 10(3):163-76. PubMed ID: 10905553
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy.
Son HW; Yokota T
Methods Mol Biol; 2018; 1828():57-68. PubMed ID: 30171534
[TBL] [Abstract][Full Text] [Related]
13. Delivery is key: lessons learnt from developing splice-switching antisense therapies.
Godfrey C; Desviat LR; Smedsrød B; Piétri-Rouxel F; Denti MA; Disterer P; Lorain S; Nogales-Gadea G; Sardone V; Anwar R; El Andaloussi S; Lehto T; Khoo B; Brolin C; van Roon-Mom WM; Goyenvalle A; Aartsma-Rus A; Arechavala-Gomeza V
EMBO Mol Med; 2017 May; 9(5):545-557. PubMed ID: 28289078
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication.
Deas TS; Binduga-Gajewska I; Tilgner M; Ren P; Stein DA; Moulton HM; Iversen PL; Kauffman EB; Kramer LD; Shi PY
J Virol; 2005 Apr; 79(8):4599-609. PubMed ID: 15795246
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotides as therapeutic agents.
Alama A; Barbieri F; Cagnoli M; Schettini G
Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
[TBL] [Abstract][Full Text] [Related]
16. Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli.
Deere J; Iversen P; Geller BL
Antimicrob Agents Chemother; 2005 Jan; 49(1):249-55. PubMed ID: 15616302
[TBL] [Abstract][Full Text] [Related]
17. Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism.
Arora V; Cate ML; Ghosh C; Iversen PL
Drug Metab Dispos; 2002 Jul; 30(7):757-62. PubMed ID: 12065433
[TBL] [Abstract][Full Text] [Related]
18. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice.
Malerba A; Thorogood FC; Dickson G; Graham IR
Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.
Ko YJ; Devi GR; London CA; Kayas A; Reddy MT; Iversen PL; Bubley GJ; Balk SP
J Urol; 2004 Sep; 172(3):1140-4. PubMed ID: 15311058
[TBL] [Abstract][Full Text] [Related]
20. Advanced morpholino oligomers: a novel approach to antiviral therapy.
Warren TK; Shurtleff AC; Bavari S
Antiviral Res; 2012 Apr; 94(1):80-8. PubMed ID: 22353544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
